Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease

Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome

(2009) Bénédicte Neven et al.   ARTHRITIS AND RHEUMATISM

Erdheim-Chester disease with predominant mesenteric localization: Lack of efficacy of interferon alpha

(2009) Antoinette Perlat et al.   JOINT BONE SPINE

Interferon alpha and neuromuscular disorders

(2009) Joerg-Patrick Stübgen   JOURNAL OF NEUROIMMUNOLOGY

Erdheim–Chester disease: Multisystem involvement and management with interferon-α

(2009) Hiroshi I. Suzuki et al.   LEUKEMIA RESEARCH

An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist

(2009) Ivona Aksentijevich et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Autoinflammatory Disease Due to Homozygous Deletion of theIL1RNLocus

(2009) Sreelatha Reddy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Autoinflammatory diseases

(2008) Isabelle Touitou et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma

(2008) Axel Hauschild et al.   CANCER

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study

(2008) Norman Ilowite et al.   CLINICAL RHEUMATOLOGY

Type I IFN induced IL1-Ra expression in hepatocytes is mediated by activating STAT6 through the formation of STAT2: STAT6 heterodimer

(2008) Lei Wan et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE